VP-102 Common Warts Phase 3 Enrollment Complete: First-Mover Opportunity Clouded by Uncontrolled Phase 2 Foundation and Undisclosed Trial Design

Verrica Completes Enrollment for Pivotal COVE-2 Trial in Common Warts

Verrica Pharmaceuticals Inc. has announced the completion of enrollment for COVE-2, the first pivotal Phase 3 trial of YCANTH® (VP-102) for the treatment of common warts. An interim statistical power analysis confirmed that no additional patients are recommended for full enrollment. The second pivotal trial, COVE-3, has already exceeded 50% of its current target enrollment ahead of schedule. Topline data for COVE-2 is anticipated in the first quarter of 2027, with remaining topline data for the overall program expected by mid-2027. This program aims to expand YCANTH's label, potentially making it the first FDA-approved prescription drug for common warts, addressing a significant unmet need in dermatology.

• Verrica Pharmaceuticals has successfully completed enrollment for its first pivotal Phase 3 trial, COVE-2, which is evaluating YCANTH® (VP-102) for common warts. A per-protocol interim analysis of powering assumptions confirmed that no additional subjects are recommended, indicating the trial is adequately designed with the current patient cohort.
• Significant progress has also been made in the second pivotal trial, COVE-3, which has already achieved over 50% of its current targeted enrollment ahead of schedule. The company expects to release topline data from COVE-2 in the first quarter of 2027, with the remaining topline data for the entire common warts program anticipated by mid-2027.
• The potential label expansion of YCANTH® into common warts is a key component of Verrica's long-term commercial strategy, offering high synergy with existing sales and marketing efforts. Common warts represent a substantial unmet need in dermatology, affecting approximately 22 million patients in the U.S. alone with no FDA-approved prescription therapies, potentially representing a multibillion-dollar commercial opportunity.

Why New Prescription Options for Common Warts Are Needed

Despite decades of available treatments, common warts continue to present significant clinical challenges across several patient populations, with recalcitrant and treatment-resistant cases representing a persistent gap in the therapeutic landscape. Recent literature highlights specific subgroups where standard-of-care options consistently fall short, driving investigational interest in novel and repurposed therapies.

• Immunocompromised patients, particularly pediatric solid organ transplant recipients, face disproportionate wart burden due to sustained immunosuppression; a study of 8 pediatric heart transplant recipients with multiple recalcitrant warts required extended cimetidine therapy (30–40 mg/kg/day for 3–6 months) to achieve resolution, with only one patient showing no clinical improvement — underscoring the difficulty of managing this population.

• Immunosuppressed children with refractory warts represent an emerging target, with case evidence demonstrating successful use of the nonavalent HPV vaccine in a 9-year-old immunosuppressed patient; broader data suggest HPV vaccination shows promise for cutaneous warts, particularly in children, young adults, and immunosuppressed individuals.

• Cryotherapy-resistant cases constitute a discrete unmet need, illustrated by four verruca patients who failed standard first-line therapy and were subsequently managed with 18% aluminum chloride solution — highlighting the lack of validated second-line options for non-responders.

• Patients with recalcitrant non-genital warts are being targeted by intralesional approaches, including comparative studies of intralesional acyclovir vs. 5-fluorouracil and intralesional quadrivalent HPV vaccine vs. candida antigen, each enrolling 60 patients — reflecting active investigation into alternatives when conventional therapies fail.

• The pediatric population broadly remains underserved from an evidence standpoint; of studies published in this space, only 4 focused exclusively on pediatric patients, indicating a significant gap in age-appropriate treatment data and pediatric-specific clinical guidance.

YCANTH's Pivotal Phase 3 Program for Common Warts

The pivotal Phase 3 program evaluating YCANTH (cantharidin 0.7% topical solution) for common warts was built on a controlled, multi-endpoint trial framework designed to assess both efficacy and safety across a defined patient population. The trials employed standardized assessment schedules and clearly delineated primary and secondary endpoints to support regulatory-grade evidence generation.

The Current Treatment Landscape for Common Warts

Common warts (verruca vulgaris) are managed through a tiered treatment framework, with therapy selection guided by lesion duration, location, clinical presentation, and patient preference. Importantly, no currently available medical or destructive therapeutic option is uniformly effective or virucidal, and the evidence base for many treatments lacks rigorous double-blind, controlled trial data — leaving the possibility of placebo effect difficult to exclude.

• First-line therapy consists of topical agents including salicylic acid, silver nitrate, and glutaraldehyde, recommended for single or few small warts of short duration (less than one year).

• Second-line therapy centers on cryotherapy, indicated when first-line treatments have failed or are contraindicated.

• Combination approaches — specifically cryotherapy combined with salicylic acid — are associated with significantly higher remission rates than either modality alone.

• Third-line options encompass a broad range of topical, intralesional, systemic, and physical destructive interventions; these are generally used off-label (without US FDA approval) and are limited in routine use by their adverse effect profiles and practical drawbacks.

• Treatment goals are focused on relieving physical and psychological discomfort and preventing autoinoculation-driven spread, rather than eradication of the underlying HPV infection.

YCANTH's Bid to Redefine Common Wart Treatment

YCANTH's Bid to Redefine Common Wart Treatment

The landscape of common wart treatment has long been characterized by a patchwork of options, none of which hold the coveted FDA-approved prescription status. Patients and clinicians navigate a world of over-the-counter remedies, off-label prescriptions, and compounded formulations, often with inconsistent efficacy and a range of adverse effects. The current literature highlights that treatments like salicylic acid offer only modest benefits, and cryotherapy's effectiveness is often inconsistent, with both carrying risks of pain, blistering, and even chemical burns. This significant unmet need sets the stage for YCANTH (VP-102), a proprietary cantharidin drug-device combination, to potentially carve out a new, regulated market segment.

Having already secured FDA approval for molluscum contagiosum, YCANTH's expansion into common warts represents a strategic move to leverage its established platform. The ongoing Phase 3 trials, COVE-2 and COVE-3, are critical steps towards offering a standardized, evidence-backed treatment. This could fundamentally shift how common warts are managed, providing a clinically validated option where none currently exists. The strategic implications are clear:

• Market Leadership: Being the first FDA-approved prescription drug for common warts would grant a significant first-mover advantage.

• Product Differentiation: The controlled formulation and delivery system of VP-102 offer a distinct advantage over variable compounded or non-prescription alternatives.

• Franchise Building: This label expansion strengthens YCANTH's position as a leading topical dermatological solution.

However, the path forward is not without considerations. While YCANTH has demonstrated efficacy and a manageable safety profile, the known local skin reactions associated with cantharidin, such as vesicles, pain, and pruritus, could influence patient adherence. Furthermore, the market for common warts is complex, with many cases resolving spontaneously and a plethora of inexpensive, albeit less effective, options readily available. Educating both healthcare providers and patients on the benefits of a prescription-grade, standardized treatment, despite its potential cost and local adverse events, will be crucial for successful market penetration. The ultimate success will hinge on demonstrating a compelling value proposition that outweighs the convenience and familiarity of existing, less regulated approaches.